Gritstone bio, Inc. (2JQ.SG)
| Previous Close | 0.0294 |
| Open | 0.0419 |
| Bid | 0.0294 x 0 |
| Ask | 0.0302 x 0 |
| Day's Range | 0.0294 - 0.0419 |
| 52 Week Range | 0.0294 - 2.7300 |
| Volume | |
| Avg. Volume | 2,242 |
| Market Cap | 3.472M |
| Beta (5Y Monthly) | 0.50 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.0100 |
| Earnings Date | Nov 06, 2024 - Nov 11, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
TipRanksGritstone Oncology Pursues Restructuring Through Chapter 11
Gritstone Oncology ( (GRTS) ) has shared an update. Gritstone bio, Inc., a biotech firm specializing in potent vaccines, has voluntarily filed for Chapter 11 bankruptcy to restructure and preserve its value while continuing operations. This move is part of a strategic process to explore alternatives and secure a stalking horse bidder to maximize value, demonstrating commitment to advancing clinical programs. Despite the filing, the company aims to maintain normal operations and minimize impact o
Business WireGritstone bio Takes Action to Preserve Value and Strengthen Capital Structure
EMERYVILLE, Calif., October 10, 2024--Gritstone bio, Inc. (Nasdaq: GRTS) ("Gritstone" or the "Company"), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today announced it has filed a voluntary petition under chapter 11 of the United States Bankruptcy Code in the United States Bankruptcy Court for the District of Delaware.
GlobeNewswireGritstone bio Announces Interim Phase 2 Data for GRANITE Individualized Neoantigen Targeting Immunotherapy in Frontline Metastatic Microsatellite Stable Colorectal Cancer
--Encouraging progression-free survival data in overall population; continued follow-up needed to allow data to mature further, especially in low ctDNA subgroup where events accrue more slowly --21% relative risk reduction of progression or death with GRANITE vs. control in all treated population (HR=0.79 [95% CI, 0.42-1.50])-- -- 38% relative risk reduction of progression or death with GRANITE vs. control in low ctDNA subgroup (HR=0.62 [95% CI, 0.23-1.70]) -- -- Strength of neoantigen specific
